TY - JOUR
T1 - MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a
AU - Sormani, Maria Pia
AU - Freedman, Mark S.
AU - Aldridge, Julie
AU - Marhardt, Kurt
AU - Kappos, Ludwig
AU - De Stefano, Nicola
N1 - Funding Information:
The study and analyses were supported by Merck KGaA , Darmstadt, Germany.
Funding Information:
LKs´ institution (University Hospital Basel) has received in the last 3 years and used exclusively for research support: steering committee, advisory board, and consultancy fees (Actelion, Addex, Bayer HealthCare, Biogen, Biotica, Genzyme, Lilly, Merck KGaA [Darmstadt, Germany], Mitsubishi, Novartis, Ono Pharma, Pfizer, Receptos, Sanofi, Santhera, Siemens, Teva, UCB, and Xenoport); speaker fees (Bayer HealthCare, Biogen, Merck KGaA [Darmstadt, Germany], Novartis, Sanofi, and Teva); support of educational activities (Bayer HealthCare, Biogen, CSL Behring, Genzyme, Merck KGaA [Darmstadt, Germany], Novartis, Sanofi, and Teva); license fees for Neurostatus products; and grants (Bayer HealthCare, Biogen, European Union, Innoswiss, Merck KGaA [Darmstadt, Germany], Novartis, Roche Research Foundation, Swiss MS Society, and Swiss National Research Foundation).
Funding Information:
Medical writing assistance was provided by Sarah Wetherill and Shaun Foley of in Science Communications, Springer Healthcare Ltd, Chester, UK, and funded by Merck KGaA, Darmstadt, Germany.
Publisher Copyright:
© 2021 The Authors
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - Background: Subcutaneous (sc) interferon (IFN) β-1a reduces relapse rates and delays disability progression in patients with MS. We examined the association of the year 1 Magnetic Resonance Imaging in MS (MAGNIMS) score with long-term clinical disease activity (CDA) -free status and confirmed disability progression in patients treated with sc IFN β-1a in PRISMS. Methods: Patients treated with sc IFN β-1a three-times-weekly (22 or 44 μg; pooled data) were classified by MAGNIMS score (0, n = 129; 1, n = 108; 2, n = 130) at year 1. Hazard ratios (HR; 95% confidence intervals [CI]) for risk of CDA and confirmed Expanded Disability Status Score (EDSS) progression were calculated by MAGNIMS score for up to 15 years of follow-up. Results: The risk of CDA was higher with a year 1 MAGNIMS score of 1 versus 0 (HR 1.82 [1.38–2.41]), 2 versus 0 (2.63 [2.01–3.45]) and 2 versus 1 (1.45 [1.11–1.89], all p < 0.0001). The same outcome was observed with the risk of confirmed EDSS progression (1 versus 0: 1.93 [1.23–3.02]; 2 versus 0: 2.95 [1.95–4.46]; 2 versus 1: 1.53 [1.05–2.23]; all p < 0.0001). Conclusion: In PRISMS, MAGNIMS score at Year 1 predicted risk of CDA and confirmed disability progression in sc IFN β-1a-treated patients over up to 15 years. PRISMS-15 clinicaltrial.gov identifier: NCT01034644
AB - Background: Subcutaneous (sc) interferon (IFN) β-1a reduces relapse rates and delays disability progression in patients with MS. We examined the association of the year 1 Magnetic Resonance Imaging in MS (MAGNIMS) score with long-term clinical disease activity (CDA) -free status and confirmed disability progression in patients treated with sc IFN β-1a in PRISMS. Methods: Patients treated with sc IFN β-1a three-times-weekly (22 or 44 μg; pooled data) were classified by MAGNIMS score (0, n = 129; 1, n = 108; 2, n = 130) at year 1. Hazard ratios (HR; 95% confidence intervals [CI]) for risk of CDA and confirmed Expanded Disability Status Score (EDSS) progression were calculated by MAGNIMS score for up to 15 years of follow-up. Results: The risk of CDA was higher with a year 1 MAGNIMS score of 1 versus 0 (HR 1.82 [1.38–2.41]), 2 versus 0 (2.63 [2.01–3.45]) and 2 versus 1 (1.45 [1.11–1.89], all p < 0.0001). The same outcome was observed with the risk of confirmed EDSS progression (1 versus 0: 1.93 [1.23–3.02]; 2 versus 0: 2.95 [1.95–4.46]; 2 versus 1: 1.53 [1.05–2.23]; all p < 0.0001). Conclusion: In PRISMS, MAGNIMS score at Year 1 predicted risk of CDA and confirmed disability progression in sc IFN β-1a-treated patients over up to 15 years. PRISMS-15 clinicaltrial.gov identifier: NCT01034644
KW - Clinical disease activity
KW - Disability progression
KW - Interferon beta-1a
KW - MAGNIMS
KW - Predictor of disease progression
KW - Scoring system
UR - http://www.scopus.com/inward/record.url?scp=85100554183&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100554183&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2021.102790
DO - 10.1016/j.msard.2021.102790
M3 - Article
AN - SCOPUS:85100554183
VL - 49
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
SN - 2211-0348
M1 - 102790
ER -